#VP61: HCV Treatment Uptake Among Marginalized People Who Inject Drugs In Norway: A Registry-Based Study

Author: Kristian Braathen Malme Kjersti Ulstein Ane Finbråthen Linda Elise Couëssurel Wüsthoff Olav Dalgard Håvard Midgard

Theme: Epidemiology and Public Health Research Year: 2021

Background: Improving HCV treatment uptake among people who inject drugs (PWID) is crucial to achieve the WHO elimination targets, but there is a paucity in data on DAA treatment uptake among PWID. The aim was to assess HCV treatment uptake and associated factors in a large cohort of PWID in Norway. Methods: Registry-based observational study where all registered users of the City of Oslo’s low-threshold social and health services for PWID between 2010-2016 were linked to HCV notifications (1990-2019; 67% HCV RNA+, 33% anti-HCV+) and prescriptions of HCV treatment, OAT and benzodiazepines (2004- 2019). HCV treatment rates were calculated using person-time of observation assuming a Poisson distribution. Factors associated with treatment uptake were explored using logistic regression analysis. Results: Among 2436 participants with notified HCV infection (median age at end of observation 45.9 years, 30.7% female, 73.3% OAT), 1118 (45.9%) received HCV treatment between 2010-2019 for an overall treatment incidence of 7.39/100 PY (95% CI 6.96-7.83). Treatment was interferon-based in 102 (9.1%) and DAA-based in 1016 (90.1%) individuals. Treatment rates increased from 1.42/100 PY (95% CI 1.12- 1.78) in the pre-DAA period (2010-2013) to 3.51/100 PY (95% CI 3.04-4.04) in the early DAA period (2014-2016; fibrosis restrictions) and 18.4/100 PY (95% CI 17.19-19.70) in the late DAA period (2017- 2019; no fibrosis restrictions), peaking at 24.07/100 PY (95% CI 21.68-26.66) in 2018 (Figure 1). DAA uptake was less likely among females (aOR 0.68; 95% CI 0.62-0.87) and more likely among participants with current OAT use (aOR 1.34; 95% CI 1.11-1.62). Conclusion: Treatment uptake among PWID increased in the DAA era. Strategies to enhance treatment among women and individuals not engaged in OAT should be addressed. Disclosure of Interest Statement: HM, OD and KU have received lecture and consultancy fees from Gilead, MSD and Abbvie. No pharmaceutical grants were received in the development of this study.

Download abstract Watch video